The role of post-transplantation cyclosporine treatment in the course of cystic fibrosis pulmonary disease: a case report

We describe the case of a 44-year-old female cystic fibrosis (CF) patient (R334W/852del22) who presented symptoms of prolonged acute respiratory infections and recurrent episodes of pneumonia. Computed tomography (CT) scan images of the chest showed that the patient presented airway and parenchymal changes throughout both lungs. She also had decreased lung function performances. In March 2004, she underwent live-related donor renal transplant and started an immunosuppressive therapy with cyclosporine. CT scan images taken respectively 2 and 6 years after transplantation documented a progressive significant size reduction of structural lung damages in both lungs and clinical signs and symptoms of improvements.

[1]  A. Bush,et al.  Distinct patterns of inflammation in the airway lumen and bronchial mucosa of children with cystic fibrosis , 2011, Thorax.

[2]  A. Bush,et al.  The Th17 pathway in cystic fibrosis lung disease. , 2011, American journal of respiratory and critical care medicine.

[3]  Eoin L. Brodie,et al.  Relationship between cystic fibrosis respiratory tract bacterial communities and age, genotype, antibiotics and Pseudomonas aeruginosa. , 2010, Environmental microbiology.

[4]  J. Gustafson,et al.  Cystic Fibrosis , 2009, Journal of the Iowa Medical Society.

[5]  V. Raia,et al.  Comprehensive Cystic Fibrosis Mutation Epidemiology and Haplotype Characterization in a Southern Italian Population , 2005, Annals of Human Genetics.

[6]  J. Bellanti,et al.  A clinical perspective of cystic fibrosis and new genetic findings: Relationship of CFTR mutations to genotype–phenotype manifestations , 2003, American journal of medical genetics. Part A.

[7]  D. Glavač,et al.  DHPLC screening of cystic fibrosis gene mutations , 2002, Human mutation.

[8]  A. Nicholson,et al.  The pathology of cystic fibrosis , 2002 .

[9]  J. Carlin,et al.  Lower airway inflammation in infants and young children with cystic fibrosis. , 1997, American journal of respiratory and critical care medicine.

[10]  L Timmermann,et al.  The mechanism of action of cyclosporin A and FK506. , 1996, Clinical immunology and immunopathology.

[11]  M. Weinberger,et al.  The relationship between infection and inflammation in the early stages of lung disease from cystic fibrosis , 1995, Pediatric pulmonology.

[12]  A. Cantin,et al.  Cystic fibrosis lung inflammation: early, sustained, and severe. , 1995, American journal of respiratory and critical care medicine.

[13]  D. Riches,et al.  Early pulmonary inflammation in infants with cystic fibrosis. , 1995, American journal of respiratory and critical care medicine.

[14]  S. Fitzsimmons.  The changing epidemiology of cystic fibrosis. , 1994, Current problems in pediatrics.

[15]  M. Brett,et al.  The value of serum IgG titres against Pseudomonas aeruginosa in the management of early pseudomonal infection in cystic fibrosis. , 1992, Archives of disease in childhood.

[16]  R E COOKE,et al.  A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine by iontophoresis. , 1959, Pediatrics.

[17]  H. Shwachman,et al.  Long-term study of one hundred five patients with cystic fibrosis; studies made over a five- to fourteen-year period. , 1958, A.M.A. journal of diseases of children.

[18]  I. Lossos,et al.  Amelioration of bleomycin-induced pulmonary injury by cyclosporin A. , 1996, Experimental lung research.